category: products


ECA is renowned for researching and manufacturing a wide range of phospholipids products. Our expertise not only lies in crafting premium sources of phosphatidylserine (PS) products – vital building blocks of cell membranes – that surpass the standards set by our competitors in the industry, but also ingredients like phosphatidylcholine (PC), phosphatidic Acid (PA), phosphatidylethanolamine (PA), phosphatidylinositol (PI) and so on.

Phosphatidylcholine (PC), a key component of the lipid bilayer, plays a crucial role in enhancing the stability, bioavailability and bioactivity of functional ingredients like Vitamin C, NMN, PQQ, CoQ10, DIM, PEA etc. in liposomal form, enabling the efficient delivery of these powerful molecules to targeted cells and tissues.

At ECA, we prioritize our commitment to research and development, ensuring that our ingredients remain at the forefront of innovation.

Furthermore, our production capabilities enable us to successfully introduce these natural ingredients into the market.

With our team of proficient scientists and a steadfast focus on quality, ECA remains poised to spearhead advancements in natural ingredients, specifically premium phospholipids.

Phosphatidylserine (PS) Series 

Phosphatidylcholine (PC) Series

Other Phospholipids

History of ECA's Premium Phospholipids


Started the development of PLD

Initiated PLD development.

Successfully got PLD in the lab.

PLD successfully obtained in the lab.

Successfully moved the PLD into mass production, and produced soy origin BioPS™ without chemical solvents.

PLD moved to mass production; soy BioPS™ produced without solvents. High-quality, sustainable, and eco-friendly.

Commercial production launched at NSF GMP facility, cost & quality improved further.

Commercial production launched at NSF GMP facility, cost & quality improved further. Successfully developed & produced Marine origin DHAPS™.

Sunflower origin SunPS™

Sunflower origin SunPS™ launched, along with the development of Micronized & WD PS, execution of clinical studies on animals, stability tests on BioPS™ and DHAPS™ & obtained a self-affirmed GRAS.

GRAS Notice ongoing

Capacity expands, ongoing GRAS notice & more clinical application studies.

Higher content and more stable DHAPS was developed;

Developed higher content, more stable DHAPS & more clinical studies on animals executed.